7 Amendments of Annie SCHREIJER-PIERIK related to 2016/2057(INI)
Amendment 192 #
Motion for a resolution
Paragraph 3
Paragraph 3
3. Stresses that transparency of the cost of development and clinical trials, whether ex ante or ex post, is crucial in order to set a fair price;
Amendment 209 #
Motion for a resolution
Paragraph 4
Paragraph 4
4. Stresses that the interests of the pharmaceutical industry in the Union favour short trials and fast access to the market;
Amendment 315 #
Motion for a resolution
Paragraph 13
Paragraph 13
13. Believes that a fair price should cover the cost of the drug development and production, plus a fair margin of profit;
Amendment 397 #
Motion for a resolution
Paragraph 19
Paragraph 19
19. Calls on the Commission to promote R&D driven by national health requirements and patients’ needs, while fostering social responsibility in the pharmaceutical sector, by setting up an EU public platform for R&D funded by contributions from profits madeearned by the pharmaceutical industry through sales to public health systems only; calls for maximum transparency on the costs of R&D, taking the legitimate scientific, public and private interests of the relevant stakeholders into account;
Amendment 410 #
Motion for a resolution
Paragraph 20
Paragraph 20
20. Calls on the Commission to analyse the overall impact of IP in promoting innovation and patients’ access to drugs, especially the impact of supplementary protection certificates (SPCs), data exclusivity or market exclusivity on competitiveness and quality of innovation, and to set strict limits on these practices;
Amendment 516 #
Motion for a resolution
Paragraph 26 a (new)
Paragraph 26 a (new)
26a. calls on the Commission to take measures to promote the development of drugs for preventative and curative geriatrics, and access to innovative drugs for patients suffering from mesothelioma and amyotrophic lateral sclerosis (ALS);
Amendment 594 #
Motion for a resolution
Paragraph 36
Paragraph 36
36. Calls on the Commission to analyse the causes of shortages, to establish a list of essential medicines and monitor compliance with Article 81 of Directive 2001/83/EU on drug shortages of supplyand the withdrawal from the market of efficient drugs for purely commercial reasons, and to promote the supply of generics;